Non-Hodgkin lymphoma

Abstract

In a prospective randomized trial conducted by SWOG, CHOP has shown equivalent efficacy to second and third generation combinations, while the toxic death rate by CHOP was the smallest among regimes studied. The group thus concluded that CHOP remains the best available treatment. However judging from past results it is not definitive that CHOP is standard. Many investigators therefore have studied to obtain higher efficacy that by CHOP. Regimes for higher dose intensity with the support of G-CSF, and high dose chemotherapy with the support of autologous hematopoietic stem cells, are under way and current results are reviewed.